CommercialPrior AuthMedium impact
Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)
Blue Cross & Blue Shield of Mississippi·MS · Rheumatology, Nephrology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their medical policy for lupus treatment drugs requiring prior authorization for Benlysta, Lupkynis, and Saphnelo. The policy establishes specific criteria for SLE and lupus nephritis treatment, with Lupkynis and Saphnelo considered not medically necessary due to formulary alternatives.
Action Required
Immediately: Billing team must ensure prior authorization is obtained before prescribing or administering Benlysta (belimumab), Lupkynis (voclosporin), or Saphnelo (anifrolumab-fnia) for BCBS Mississippi patients. Update EMR templates to include lupus nephritis classification documentation and standard therapy requirements. Verify formulary coverage through patient member ID search before prescribing. Claims will be denied without proper prior authorization.